Lotte Biologics signs antibody drug CMO deal with UK’s Ottimo Pharma
BOSTON – Lotte Biologics Co. has signed a deal to manufacture an antibody therapy for British biotech startup Ottimo Pharma as the South Korea...
S.Korea’s CDMO giant Samsung Biologics to offer CRO services
Samsung Biologics Co., the world’s largest contract drugmaker, will enter the contract research organization (CRO) market by leveraging its va...
Samsung Biologics drives foreign lead in Korea’s biotech supply chain
A surge in orders from Samsung Biologics Co., the world’s largest contract drugmaker, has propelled South Korea to the forefront of global rev...
Samsung Biologics to spin off biosimilar unit Samsung Bioepis
Samsung Biologics Co., the world’s largest contract drugmaker, will undergo a strategic split to separate its contract development and manufac...
Samsung Biologics bags $514 mn CMO contract from US pharma
Samsung Biologics Co., the world’s largest contract manufacturing organization (CMO), said on Monday it has secured a $5.14 million order from...
Chong Kun Dang to build new plant for foray into biologics market
Chong Kun Dang Pharmaceutical Corp. is discussing building a research center and a plant in Siheung, about 30 kilometers southwest of Seoul, with th...
Samsung Biologics shares fly high to be Korea’s third most valuable firm
Samsung Biologics Co., the world’s largest contract drugmaker, has become South Korea’s third most valuable stock on the country’s...
Samsung Biologics posts record 2024 sales, operating profit as it goes global
South Korea's Samsung Biologics Co., the world’s largest contract drugmaker, on Wednesday posted its largest-ever annual sales and operating p...
Lotte Biologics eyes first ADC CDMO order in 2025
SAN FRANCISCO -- Lotte Biologics Co., the drug consignment development and production unit of South Korean conglomerate Lotte Group, will seek to wi...
Samsung Biologics signs $1.4 bn CMO deal with European pharma
South Korea's Samsung Biologics Co., the world’s largest contract drugmaker, said on Tuesday it signed a $1.4 billion contract manufacturing o...
Samsung Biologics signs initial deal with LigaChem Bio on ADC production
Samsung Biologics Co., the world’s largest contract drugmaker, said on Thursday it has signed an initial agreement with LigaChem Biosciences I...
SK Bioscience, Sanofi to develop next-gen pneumococcal vaccines
South Korea's SK Bioscience Co. said on Friday it signed an expanded agreement with Sanofi to co-develop next-generation pneumococcal conjugate vacc...
Samsung Biologics wins $668 million CDMO deal with European pharma
Samsung Biologics Co., the world’s largest contract drugmaker, said on Wednesday it has signed two drug manufacturing contracts worth a combin...
SK Bioscience's SKYCellflu approved in Indonesia
SK Bioscience Co., a bio and pharmaceutical affiliate of South Korea's SK Group, said on Wednesday that The Indonesian Food and Drug Authority BPOM ...
Enormous market ahead for Hopae, S.Korean DID pioneer
To Hopae Inc., a digital identity solution-developing startup native to South Korea, its home market is small. After successfully accommodating more...
SK Bioscience sells stake in US vaccine developer Novavax
SK Bioscience Co., a drug-making arm of South Korea's No. 2 conglomerate SK Group, has sold a stake in Nasdaq-listed vaccine developer Novavax Inc. ...
IMBiologics transfers autoimmune disease drug tech to Huadong Pharma
South Korea's antibody-based biotech company IMBiologics announced on Friday that it signed a contract to transfer the technology of its autoimmune ...
Biotech stocks, foreigners’ top pick in Korea amid panic selling
Foreigners and institutional investors in the South Korean stock market picked biotechs as their favorite shares in hopes of a biopharma stock jump ...
Samsung’s biotech duo on a roll with $1.1 bn CMO order
Samsung Group is on track to rise to the top of biosimilar companies in the world and become South Korea’s largest drug maker for contract man...
Lotte Biologics targets $1.1 billion in sales with new bio plants
South Korean biopharmaceutical company Lotte Biologics Co. said on Wednesday it is aiming for 1.5 trillion won ($1.1 billion) in annual sales by 203...
SK Bioscience to buy German vaccine maker IDT Biologika for $244 mn
South Korea’s vaccine developer SK Bioscience Co. will acquire a controlling stake in the world’s top 10 vaccine firm IDT Biologika GmbH...
Samsung Biologics eyes windfall gain amid US-China row
SAN DIEGO – Samsung Biologics Co. is enjoying a stream of contract development and manufacturing order inquiries from big pharmaceutical compa...
EuBiologics gets WHO certification for cholera vaccine facility
South Korea's EuBiologics Co. announced on Friday that the vaccine bulk production facility at its Chuncheon Plant No. 2 for the oral cholera vacc...
SK Bioscience exports Sky Cellflu to Thailand
South Korea's SK Bioscience Co. announced on Thursday that it has shipped about 440,000 doses (for single-dose administration) of its cell-cultured ...
Samsung Biologics signs ADC CDO deal with LegoChem Bio
Samsung Biologics Co. has agreed with South Korean biotech company LegoChem Biosciences Inc. to provide contract development organization (CDO) serv...
Lotte Biologics, NJ Bio to jointly develop ADC
South Korea's Lotte Biologics Co. announced on Monday that it has signed a strategic business agreement with NJ Bio, a US-based preclinical and clin...
SK Bioscience start to deliver Novavax COVID-19 vaccine
South Korea's SK Bioscience Co. announced on Tuesday that it started to deliver the Novavax COVID-19 vaccine against XBB.1.5 variant.According to No...
SK Bioscience applies Phase 3 trials in US for pneumococcal vaccine
South Korea's SK Bioscience Co. announced on Monday that it submitted the Investigational New Drug (IND) application for the Phase 3 clinical trial ...
Samsung Biologics reaches record-breaking annual orders
Samsung Biologics Co., the world’s top contract manufacturing organization (CMO) by capacity, surpassed the annual contract manufacturing orde...
Korea to invest $200 mn in new drugs, vaccines by 2028
South Korea’s health ministry will allocate 261.6 billion won ($200.2 million) for two funds over the next four years to boost private sector ...
